Latest Breaking News On - Platinum resistant ovarian cancer - Page 5 : vimarsana.com

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaMirvetuximab soravtansineConor richardsonTaylor schreiberGeorge frommPreclinical pipeline developmentExchange commissionDevelopment rd expensesProduct developmentAmerican association for cancer research annual meetingDiscontinuation of clinical developmentShattuck labs incHeat biologics incGamma deltat cell engagerSuresh de silva

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesConor richardsonseniorJonathan millerTaylor schreiberAl programExchange commissionDevelopment rd expensesSociety for immunotherapy of cancerInvestor relationsshattuck labs incShattuck labs incGamma deltat cell engagerAnnual meetingChief executive officerBusiness highlightsStage pipeline

ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting - Press Release

Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9

United statesMirvetuximab soravtansineAnna berkenblitUrsula matulonisRoche groupHarvard medical schoolDana farber cancer instituteSociety of gynecologic oncologyDivision of gynecologic oncologyImmunogen incTrial met primary endpointConfirmed objective response rateUpdated median durationDemonstrated meaningful anti tumor activityConsistent safetyFavorable tolerability

InxMed Raised $50 million in Series B Financing to Advance Innovative Therapies to Drug-resistance Cancers

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesZaiqi wangZhua yiPrnewswire inxmed co ltdInxmed co ltdGrowth fundHosencare fundBoehringer ingelheimDrug administrationEnnovation ventureMetastatic melanomaPlatinum resistant ovarian cancerTriple negative breast cancerFast trackChief executive officerManaging director

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

[December 29, 2020] VBL Therapeutics Announces First Patient in Europe in the OVAL Trial Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian CancerÂ into EuropeÂ TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) VBL TherapeuticsÂ (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date. âVB-111 is our proprietary anti-cancer gene therapy product candidate that has shown overall survival benefit across multiple tumor types,â said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. âWe are pleased to expand the OVAL potential registration study of VB-111 in patients with late stage ovarian cancer to E

Irina kofflerDror haratsExchange commissionData safety monitoring committeeVascular biogenics ltdEuropean commissionFoundation incAnnounces first patientRegistration studyPlatinum resistant ovarian cancerChief executive officerOrphan designationBiogenics ltdஇரினா கோஃப்லர்பரிமாற்றம் தரகுதகவல்கள் பாதுகாப்பு கண்காணிப்பு குழு